Technical Analysis for CORT - Corcept Therapeutics Incorporated

Grade Last Price % Change Price Change
D 23.88 3.02% 0.70
CORT closed up 3.02 percent on Thursday, April 22, 2021, on approximately normal volume.
Earnings due: May 3
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Up Down Up
Historical CORT trend table...

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
180 Bearish Setup Bearish Swing Setup 5.99%
MACD Bullish Signal Line Cross Bullish 4.28%
NR7 Range Contraction 4.10%
Oversold Stochastic Weakness 4.10%
Slingshot Bearish Bearish Swing Setup 4.05%
Bullish Engulfing Bullish 4.05%
Oversold Stochastic Weakness 4.05%
NR7 Range Contraction 7.18%
Down 3 Days in a Row Weakness 7.18%
Older End-of-Day Signals for CORT ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 3% about 13 hours ago
Up 2% about 16 hours ago
60 Minute Opening Range Breakout about 16 hours ago
20 DMA Resistance about 17 hours ago
Up 1% about 17 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Corcept Therapeutics Incorporated Description

Corcept Therapeutics Incorporated, a pharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders in the United States. The company focuses on disorders that are associated with a steroid hormone called cortisol. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also involved in an on-going Phase III study of mifepristone, the active ingredient in Korlym, for treatment of the psychotic features of psychotic depression. In addition, it discovers and develops three series of novel selective GR-II antagonists. The company has research and development agreements with Argenta Discovery Limited; Sygnature Discovery Limited; ICON Clinical Research, L.P.; and MedAvante, Inc. as well as has a patent license from Stanford University for developing mifepristone. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.


Sector: Healthcare
Industry: Biotechnology
Keywords: Pharmaceutical Organ Systems Surgery Diabetes Clinical Research Disorders Endocrine System Glucose Hormones Diabetes Mellitus Depression Psychiatric Disorders Cushing's Syndrome Hyperglycemia Stanford University Cortisol Endogenous Cushing's Syndrome

Is CORT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 31.18
52 Week Low 11.91
Average Volume 526,827
200-Day Moving Average 21.39
50-Day Moving Average 24.86
20-Day Moving Average 23.34
10-Day Moving Average 22.85
Average True Range 0.83
ADX 26.13
+DI 20.11
-DI 22.12
Chandelier Exit (Long, 3 ATRs ) 23.22
Chandelier Exit (Short, 3 ATRs ) 24.62
Upper Bollinger Band 24.67
Lower Bollinger Band 22.01
Percent B (%b) 0.7
BandWidth 11.39
MACD Line -0.53
MACD Signal Line -0.67
MACD Histogram 0.1386
Fundamentals Value
Market Cap 2.77 Billion
Num Shares 116 Million
EPS 0.89
Price-to-Earnings (P/E) Ratio 26.83
Price-to-Sales 8.08
Price-to-Book 5.54
PEG Ratio 0.61
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 25.25
Resistance 3 (R3) 25.13 24.55 25.02
Resistance 2 (R2) 24.55 24.21 24.61 24.94
Resistance 1 (R1) 24.22 23.99 24.39 24.34 24.87
Pivot Point 23.64 23.64 23.73 23.70 23.64
Support 1 (S1) 23.31 23.30 23.48 23.43 22.89
Support 2 (S2) 22.73 23.08 22.79 22.82
Support 3 (S3) 22.40 22.73 22.74
Support 4 (S4) 22.52